Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan

doi:10.4239/wjd.v4.i6.358

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6451)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

451

WORD

338

HTML

3073

Figures (1-2)

329

Tables (1-2)

142

Sum=4333

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1048

Download

1070

Sum=2118

Dec 15, 2013 (publication date) through Jun 1, 2024

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Diabetes. Dec 15, 2013; 4(6): 358-364
Published online Dec 15, 2013. doi: 10.4239/wjd.v4.i6.358

Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan

Abhijit Shete, Aheson Shaikh, K Javeed Nayeem, Lily Rodrigues, Mohamed Sheikamunadeen Sadiq Ali, Parag Shah, Rajiv Khanna, Sarfaraj Majid, Sabeer A Rasheed, Shehla Shaikh, Tawfiqur Rahman

Abhijit Shete, Medical Department, Novartis Pharma AG, CH-4002 Basel, Switzerland

Aheson Shaikh, Diabetes Care Centre, Dil Shad Villa, Aurangabad 431003, India

K Javeed Nayeem, Bibi Ayesha Mili Hospital, Mysore 570007, India

Lily Rodrigues, Suraksha Multi Speciality Hospital, Hyderabad 500072, India

Mohamed Sheikamunadeen Sadiq Ali, Irfan Cardiac and Diabetic Clinic, Ramanathapuram 623503, India

Parag Shah, Gujarat Endocrine Centre, Ahmedabad 380006, India

Rajiv Khanna, Khanna Clinic, Gole Darwaza, Radhey lal, Chowk, Lucknow 226003, India

Sarfaraj Majid, B P Poddar Hospital, Kolkata 700023, India

Sabeer A Rasheed, Dr. Rasheed’s Diabetes Speciality Centre, Trivandrum 695011, India

Shehla Shaikh, KGN Diabetes & Endocrinology Center, Mumbai 400027, India

Tawfiqur Rahman, G D Diabetic Institute, Kolkata 700017, India

Author contributions: Shete A, Nayeem KJ, Rodrigues L, Ali MSS, Shah P, Khanna R, Majid S, Rasheed SA, Shaikh S and Rahman T served as the investigators for this study; all authors participated in the development and writing of the paper and approved the final manuscript for publication.

Supported by Novartis Healthcare Private Limited, India

Correspondence to: Dr. Abhijit Shete, MD, Medical Department, Novartis Pharma AG, Core Technology Area, CH-4002, Basel, Switzerland. abhijit.shete@novartis.com

Telephone: +41-616-963648 Fax: +41-613-243571

Received: June 20, 2013
Revised: September 20, 2013
Accepted: October 17, 2013
Published online: December 15, 2013

Core Tip

Core tip: Management of glycemic control in diabetes patients fasting during Ramadan has been recognized as a critically important health challenge worldwide. India has the world’s second largest diabetes population and caters large Muslim community; however, there is limited data available exploring the effect of treatments in these fasting diabetes patients. This non-interventional, multicenter, double-arm study compared the effect of vildagliptin with sulfonylureas on hypoglycemic events, HbA_1c, blood glucose levels, and response rate in 97 fasting diabetic patients during Ramadan in real-world setting. Vildagliptin appears to be an attractive treatment option for diabetes patients fasting during Ramadan.